Pacific Biosciences reported Q2 revenues of $39.01 million, missing estimates and guiding 2026 revenues down, below consensus. Operating and net losses remain sizable, with cash now under $237 million and nearly $645 million in debt outstanding. PACB trades at 2.4x expected 2026 revenues, a steep discount to peers, reflecting weaker financials and growth prospects.